NTHI Stock Analysis: Buy, Sell, or Hold?
NTHI - NeOnc Technologies Holdings, Inc. Common Stock
$4.56
-0.15 (-3.18%)
▼
5d:
-1.51%
30d:
+30.66%
90d:
-5.69%
WAIT
LOW Confidence
Analysis Updated: Aug 26, 2026 12:00 AM ET
Earnings: Aug 17, 2026
0d
Get Alerted When NTHI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NTHI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NTHI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NTHI is currently trading at $4.56, which is considered extended relative to its 30-day fair value range of $3.28 to $4.52.
Technical Outlook: Technically, NTHI is in a downtrend. Immediate support is located at $3.13, while resistance sits at $5.82. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: NTHI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.00 (+250.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTHI is in a downtrend. Immediate support is located at $3.13, while resistance sits at $5.82. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: NTHI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.00 (+250.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.28 -
$4.52
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 250.9% below Wall St target ($16.00)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.28 -
$4.52
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.13
Resistance Level
$5.82
Current Trend
Downtrend
Technical data as of
Aug 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.53
Wall Street Target
$16.00
(+250.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 26, 2026 11:44 PM ET
Data refreshes hourly during market hours. Next update: 12:44 AM
Data refreshes hourly during market hours. Next update: 12:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTHI showing a specific setup today?
Insider Activity (6 Months)
8
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Yousha Neman-Ebrahim
BUY
500 shares
2026-04-23
Amir F Heshmatpour
BUY
10000 shares
2026-04-23
Amir F Heshmatpour
BUY
10000 shares
2026-04-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 35 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 36 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 48 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$678 | 55 HOLD |